CY1122390T1 - Μεθοδοι χρησης της il-21 για την προσαρμοστικη ανοσοθεραπεια και την ταυτοποιηση καρκινικων αντιγονων - Google Patents

Μεθοδοι χρησης της il-21 για την προσαρμοστικη ανοσοθεραπεια και την ταυτοποιηση καρκινικων αντιγονων

Info

Publication number
CY1122390T1
CY1122390T1 CY20161101139T CY161101139T CY1122390T1 CY 1122390 T1 CY1122390 T1 CY 1122390T1 CY 20161101139 T CY20161101139 T CY 20161101139T CY 161101139 T CY161101139 T CY 161101139T CY 1122390 T1 CY1122390 T1 CY 1122390T1
Authority
CY
Cyprus
Prior art keywords
methods
cell
antigons
cancer
identification
Prior art date
Application number
CY20161101139T
Other languages
English (en)
Inventor
Cassian Yee
Original Assignee
Fred Hutchinson Cancer Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Research Center filed Critical Fred Hutchinson Cancer Research Center
Publication of CY1122390T1 publication Critical patent/CY1122390T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464488—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464492—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

Περιγράφονται μέθοδοι για την προετοιμασία ex vivo καλλιεργειών Τ-κυττάρων χρησιμοποιώντας συνθέσεις IL-21 για χρήση στην προσαρμοστική ανοσοθεραπεία. Καλλιέργειες ενός πληθυσμού μη τελικά διαφοροποιημένων Τ-κυττάρων, είτε απομονωμένων είτε παρουσία μονοπύρηνων κυττάρων περιφερικού αίματος, εκτίθενται σε ένα ή περισσότερα καρκινικά αντιγόνα και, παρουσία συνθέσεων IL-21 και αντιγονοπαρουσιαστικών κυττάρων (APC), ο πληθυσμός Τ-κυττάρων που προκύπτει διαθέτει ενισχυμένη αντιγονική ειδικότητα και μπορεί να επανεισαχθεί στον ασθενή. Γνωστοποιούνται, επίσης, μέθοδοι για την ταυτοποίηση καρκινικών αντιγόνων μέσω καλλιέργειας πληθυσμών Τ-κυττάρων που έχουν εκτεθεί σε συνθέσεις IL-21 και APC παρουσία καρκινικού υλικού.
CY20161101139T 2004-11-24 2016-11-09 Μεθοδοι χρησης της il-21 για την προσαρμοστικη ανοσοθεραπεια και την ταυτοποιηση καρκινικων αντιγονων CY1122390T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63072704P 2004-11-24 2004-11-24
PCT/US2005/042782 WO2006065495A2 (en) 2004-11-24 2005-11-23 Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens

Publications (1)

Publication Number Publication Date
CY1122390T1 true CY1122390T1 (el) 2020-07-31

Family

ID=36588349

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161101139T CY1122390T1 (el) 2004-11-24 2016-11-09 Μεθοδοι χρησης της il-21 για την προσαρμοστικη ανοσοθεραπεια και την ταυτοποιηση καρκινικων αντιγονων

Country Status (12)

Country Link
US (5) US20060269973A1 (el)
EP (1) EP1814580B1 (el)
JP (1) JP2008521406A (el)
CA (1) CA2587136A1 (el)
CY (1) CY1122390T1 (el)
DK (1) DK1814580T3 (el)
ES (1) ES2601896T3 (el)
HU (1) HUE030210T2 (el)
LT (1) LT1814580T (el)
PL (1) PL1814580T3 (el)
PT (1) PT1814580T (el)
WO (1) WO2006065495A2 (el)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
DE10112851C1 (de) 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
KR101236177B1 (ko) * 2004-05-20 2013-02-22 지모제넥틱스, 인코포레이티드 Ｉｌ-21 및 단클론성 항체 요법을 이용한 암 치료 방법
EP1814580B1 (en) 2004-11-24 2016-08-10 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
US20080131415A1 (en) * 2006-11-30 2008-06-05 Riddell Stanley R Adoptive transfer of cd8 + t cell clones derived from central memory cells
EP1932537A1 (en) * 2006-12-12 2008-06-18 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Expression of transgenic T cell receptors in LAK-T cells
CA3028038C (en) 2007-05-11 2021-08-10 Altor Bioscience Corporation Fusion molecules and il-15 variants
WO2009045308A2 (en) 2007-10-03 2009-04-09 Fred Hutchinson Cancer Research Center Enhanced generation of cytotoxic t-lymphocytes by il-21 mediated foxp3 suppression
EP2365823B1 (en) 2008-10-30 2016-11-30 Yeda Research And Development Company Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
US9421228B2 (en) 2008-10-30 2016-08-23 Yeda Research And Development Co. Ltd. Use of anti third party central memory T cells for anti-leukemia/lymphoma treatment
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
CN101824400B (zh) * 2009-03-05 2012-08-08 中国科学院微生物研究所 一种放大增殖抗原特异性t细胞的方法
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
CA2811734C (en) 2010-09-21 2021-11-23 Altor Bioscience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
JP2014511704A (ja) 2011-04-13 2014-05-19 イミュニカム・エイビイ Ｔ細胞のプライミングのための方法
KR102028340B1 (ko) * 2011-04-13 2019-10-04 이뮤니쿰 에이비 항원-특이적 t 세포의 증식 방법
US9234026B2 (en) 2011-07-21 2016-01-12 University of Pittsburgh—of the Commonwealth System of Higher Education Apolipoprotein E polypeptides and their use
SG11201400513PA (en) 2011-09-08 2014-06-27 Yeda Res & Dev Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
US10532088B2 (en) 2014-02-27 2020-01-14 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
CA2947290A1 (en) 2014-05-05 2015-11-12 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
KR102503476B1 (ko) 2014-06-30 2023-02-24 알토 바이오사이언스 코포레이션 Il-15-베이즈드 분자 및 이의 사용 방법
CA2961654A1 (en) 2014-09-19 2016-03-24 City Of Hope Costimulatory chimeric antigen receptor t cells targeting il13r.alpha.2
JP6737778B2 (ja) * 2014-10-01 2020-08-12 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗原およびアジュバントとしてのインターロイキン−２１を有するワクチン
JP6599450B2 (ja) 2014-10-02 2019-10-30 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
US10421751B2 (en) 2015-05-05 2019-09-24 Lycera Corporation Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
AU2016276947A1 (en) 2015-06-11 2017-12-14 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
EP4286511A3 (en) * 2015-06-12 2024-03-06 Lentigen Technology, Inc. Method to treat cancer with engineered t-cells
EP3322424B1 (en) 2015-07-16 2023-10-11 Yeda Research and Development Co., Ltd. Use of anti third party central memory t cells
CA2999294A1 (en) * 2015-09-25 2017-03-30 Altor Bioscience Corporation Interleukin-15 superagonist significantly enhances graft-versus-tumor activity
SG11201811408PA (en) 2016-06-24 2019-01-30 Univ Mcmaster Adoptive cell transfer and oncolytic virus combination therapy
WO2018031811A1 (en) * 2016-08-10 2018-02-15 Aurelius Biotherapeutics, Llc Cell therapy compositions and methods of use thereof
KR20190091264A (ko) 2016-10-21 2019-08-05 알토 바이오사이언스 코포레이션 다량체 il-15 기반 분자
CN110392736A (zh) 2017-01-18 2019-10-29 耶达研究及发展有限公司 遗传修饰的反抑细胞及其在免疫治疗中的用途
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
EP3572502B1 (en) * 2017-01-20 2023-01-11 Kyoto University Method for producing cd8alpha +beta + cytotoxic t cells
EP3655027A4 (en) 2017-07-21 2021-04-21 Berkeley Lights, Inc. SYNTHETIC ANTIGEN PRESENTATION SURFACES, COVALENTLY FUNCTIONALIZED SURFACES, ACTIVATED T-LYMPHOCYTES AND THEIR USES
TW202027761A (zh) 2018-09-21 2020-08-01 美商柏克萊燈光有限公司 功能化孔盤、其製備方法及用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
ATE476496T1 (de) 1996-03-04 2010-08-15 Calyx Bio Ventures Inc Modifizierte schnellvermehrungsmethode ('modified-rem') zur in vitro vermehrung von t-lymphozyten
US20010031253A1 (en) 1996-07-24 2001-10-18 Gruenberg Micheal L. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6307024B1 (en) * 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
JP2004512030A (ja) * 2000-09-15 2004-04-22 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 特異的細胞溶解性ｔ細胞応答を誘導するための組成物および方法
AU2003202908A1 (en) * 2002-01-03 2003-07-24 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
JP2006514601A (ja) * 2002-06-07 2006-05-11 ザイモジェネティクス インコーポレイティッド ガンおよびその他の治療用途におけるｉｌ−２１の使用方法
WO2004042041A1 (en) * 2002-11-07 2004-05-21 Johnson & Johnson Research Pty Limited A means of producing and utilising a population of disease specific cytotoxic t-lymphoctyes
JP4870432B2 (ja) * 2003-08-22 2012-02-08 タカラバイオ株式会社 細胞傷害性リンパ球の製造方法
EP1814580B1 (en) 2004-11-24 2016-08-10 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
WO2006063301A1 (en) 2004-12-10 2006-06-15 Maxcyte, Inc. Genetically modified tumor cells as cancer vaccines
WO2006116301A1 (en) 2005-04-22 2006-11-02 The Johns Hopkins University Neuroprotective compounds for treating optic neuropathies
EP1795599A1 (en) 2005-12-09 2007-06-13 Schuler, Gerold, Prof. Dr. Methods for generating antigen-specific effector T cells
WO2009045308A2 (en) 2007-10-03 2009-04-09 Fred Hutchinson Cancer Research Center Enhanced generation of cytotoxic t-lymphocytes by il-21 mediated foxp3 suppression
AU2014339926B2 (en) 2013-10-25 2018-02-08 Board Of Regents, The University Of Texas System Polyclonal gamma delta T cells for immunotherapy
CN117143814A (zh) 2014-11-17 2023-12-01 阿迪塞特治疗公司 工程化的γδ T细胞
GB201707048D0 (en) 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
MX2020003129A (es) 2017-09-20 2020-10-12 Neximmune Inc Composiciones celulares que comprenden linfocitos t específicos para antígenos para una terapia adoptiva.
EP3773626A4 (en) 2018-03-28 2022-01-05 Board of Regents, The University of Texas System USING HISTONE MODIFIERS TO REPROGRAM LYMPHOCYTES AND EFFECTORS

Also Published As

Publication number Publication date
US20100310533A1 (en) 2010-12-09
US20190316088A1 (en) 2019-10-17
ES2601896T3 (es) 2017-02-16
LT1814580T (lt) 2016-12-12
PL1814580T3 (pl) 2017-03-31
HUE030210T2 (en) 2017-04-28
EP1814580B1 (en) 2016-08-10
US9951310B2 (en) 2018-04-24
WO2006065495A2 (en) 2006-06-22
PT1814580T (pt) 2016-11-11
CA2587136A1 (en) 2006-06-22
US11306289B2 (en) 2022-04-19
EP1814580A2 (en) 2007-08-08
US20220204933A1 (en) 2022-06-30
US20150023938A1 (en) 2015-01-22
DK1814580T3 (en) 2016-12-12
JP2008521406A (ja) 2008-06-26
WO2006065495A3 (en) 2006-09-08
US20060269973A1 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
CY1122390T1 (el) Μεθοδοι χρησης της il-21 για την προσαρμοστικη ανοσοθεραπεια και την ταυτοποιηση καρκινικων αντιγονων
Schumacher et al. A vaccine targeting mutant IDH1 induces antitumour immunity
CY1112293T1 (el) Χρηση των il-7 και il-15 για τη γενετικη τροποποιηση μνημονικων τ λεμφοκυτταρων
PL2102331T3 (pl) Szczepionka przeciwnowotworowa otrzymana z prawidłowych, chemicznie modyfikowanych komórek CD4+
RU2008122550A (ru) Композиции и способы индуцирования активации незрелых моноцитарных дендритных клеток
IL218447A0 (en) Co-culture lymphoid tissue equivalent (lte) for an artificial immune system (ais)
SI1404811T1 (sl) Ogljikov monoksid izboljša rezultate pri presaditvi tkiva in organov ter prepreči apoptozo
JP2008519014A5 (el)
Lion et al. Poly (I: C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC
WO2009114085A3 (en) Allogeneic cancer cell-based immunotherapy
KR101384203B1 (ko) 개 유래의 자연살해세포의 대량 증식방법
Ayyoub et al. Assessment of vaccine-induced CD4 T cell responses to the 119-143 immunodominant region of the tumor-specific antigen NY-ESO-1 using DRB1* 0101 tetramers
Siurala et al. Syngeneic syrian hamster tumors feature tumor-infiltrating lymphocytes allowing adoptive cell therapy enhanced by oncolytic adenovirus in a replication permissive setting
AR060424A1 (es) Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
Santini et al. Advances in the use of dendritic cells and new adjuvants for the development of therapeutic vaccines
Zhang et al. Human embryonic stem cells-a potential vaccine for ovarian cancer
CN110484504A (zh) 一种用于免疫治疗原发性肝细胞肝癌的细胞亚群及其制备方法
von Bergwelt-Baildon et al. Correspondence re R. Lapointe et al., CD40-stimulated B Lymphocytes Pulsed with Tumor Antigens Are Effective Antigen-presenting Cells That Can Generate Specific T Cells. Cancer Res 2003; 63: 2836–43.
CY1111813T1 (el) Αντικαρκινικο εμβολιο που περιλαμβανει αλλογονιδιακα ή ξενογονιδιακα καρκινικα κυτταρα
GB2435598A (en) Methods for supporting and producing human cells and tissues in non-human mammal hosts
DE60040672D1 (de) Antikörper-abhängige vergrösserung der alphavirus-infektvität
GB2379446A (en) Cells,culture methods and their uses
MX2022015638A (es) Vacuna de celulas tumorales alogenicas.
WO2002068451A3 (en) Sperm protein 17 for the diagnosis and treatment of cancer
Weng et al. Targeting B-cell malignancies through human B-cell receptor specific CD4+ T cells